NASDAQ · TRML
Tourmaline Bio, Inc.
$47.98$0.00 (0.0%)
Tourmaline Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.6% below the high.
Loading market information…
NASDAQ · PRDS · USD
Stock price, earnings
Quote as of Aug 30, 2023, 07:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Pardes Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.6% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Pardes Biosciences, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, developing, and marketing groundbreaking treatments. The company's core objective is to improve outcomes for patients battling life-threatening illnesses. Its primary investigational therapy, PBI-0451, is currently progressing through clinical development with the aim of both treating and preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and their related health issues. Established in 2020, Pardes Biosciences maintains its corporate headquarters in Carlsbad, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:19 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$47.98$0.00 (0.0%)
Tourmaline Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.6% below the high.
$0.88-$0.08 (-8.0%)
Selecta Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.72% below the high.
$1.54-$0.02 (-1.28%)
NGM Biopharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.16% below the high.
$0.63+$0.04 (+7.29%)
Sesen Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.84% below the high.
$2.23+$0.04 (+1.83%)
Paratek Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.9% below the high.
$2.65-$0.01 (-0.38%)
Kinnate Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.12% below the high.
$4.91-$0.04 (-0.81%)
Decibel Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 9.07% below the high.
$5.50-$0.67 (-10.8%)
Graybug Vision, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.91% below the high.
